Ir para o conteúdo principal

Cocrystal Pharma (NASDAQ: COCP) — Perfil da empresa, notícias e dados financeiros

Logo de Cocrystal Pharma
COCP Cocrystal Pharma
Cocrystal Pharma primary media
Perfil da empresa

Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) is a dynamic biotechnology firm focused on discovering, developing, and commercializing novel antiviral therapeutics. The company employs unique proprietary technologies to create first-in-class and best-in-class antiviral drugs aimed at treating diseases caused by the most serious and widespread viruses, including influenza, coronavirus, and hepatitis C. Cocrystal Pharma's mission revolves around leveraging its innovative drug discovery platform to generate effective treatments that can address unmet medical needs in the fight against viral infections. Through strategic collaborations and internal research programs, it actively pursues the development of new antiviral compounds, striving to lead advancements in the field of antiviral drug development. With a commitment to innovation and improving patient care, Cocrystal Pharma is dedicated to achieving new milestones in antiviral therapy.

Resumo

Public USParticipação acionária
2006Ano de fundação
17Funcionários
Bothell, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Cocrystal Pharma

  • Development of broad-spectrum antiviral drugs for the treatment of coronavirus infections, including COVID-19.
  • Research on inhibitors targeting the replication machinery of influenza viruses.
  • Advancements in antiviral compounds for the treatment of hepatitis C virus (HCV).
  • Exploration of novel therapies aimed at combatting norovirus infections.
  • Investigation into potential treatments for human rhinovirus (HRV).
  • Progress in the discovery of antiviral agents for the treatment of Zika virus infections.

equipe executiva do Cocrystal Pharma

  • Roger D. KornbergCo-Founder, Independent Chairman, Chief Scientist & Chairman of Scientific Advisory Board
  • Sam LeeChief Scientific Officer, Co-Founder & President
  • James J. MartinCFO & Corporate Secretary
  • James R. SapirsteinChief Executive Officer

Principais indicadores financeiros

Resultados divulgados pela Cocrystal Pharma, em USD.

Cap. de mercado
19,1 mi
Receita (TTM)
330 mil
P/L
—
LPA (diluído, TTM)
-0.8
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Cocrystal Pharma
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-9 mi-8,8 mi
0-17,9 mi-17,5 mi
0-18,6 mi-18 mi
0-38,8 mi-38,8 mi